UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
report (date of earliest event reported): September 20, 2006
ZIOPHARM
Oncology, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-32353
|
84-1475642
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1180
Avenue of the Americas, 19th
Floor
New
York, NY 10036
(Address
of principal executive offices) (Zip Code)
(646)
214-0700
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01. Other Events.
On
September 20, 2006, the Company issued a press release announcing that it had
received approval for its application to list its common shares on The NASDAQ
Capital Market. The Company’s common shares will begin trading on The NASDAQ
Capital Market on Friday, September 22, 2006 under the symbol “ZIOP.” The
trading of ZIOPHARM’s shares on the Over-the-Counter Bulletin Board will cease
at the close of business on Thursday, September 21, 2006.
Item
9.01 Financial Statements and Exhibits.
| (d) |
Exhibits.
|
| 99.1 |
Press
Release dated September 20, 2006.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Date: September 20, 2006 |
ZIOPHARM
Oncology, Inc.:
(REGISTRANT)
|
|
| |
|
|
| By: | /s/ Richard E. Bagley | |
|
RICHARD E. BAGLEY, President, |
||
| Chief Operating Officer and Chief Financial Officer | ||
Exhibit
Index
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release date September 20, 2006
|
Exhibit
99.1
ZIOPHARM
Oncology, Inc. Receives NASDAQ Approval for Capital Market Listing; ZIOPHARM
Shares to Begin Trading on the NASDAQ Capital Market on Friday, September 22,
2006 Under the Symbol ''ZIOP''
NEW
YORK--(BUSINESS WIRE)--Sept. 20, 2006--
ZIOPHARM
Oncology, Inc. (OTCBB: ZIOP.OB),
a
biopharmaceutical company focused on better cancer medicine, received approval
of its application to list its common shares on the NASDAQ Capital Market.
The
Company's common shares will begin trading on NASDAQ on Friday, September 22,
2006 under the symbol ZIOP. The trading of the Company's shares on the
Over-the-Counter Bulletin Board will cease on the close of business on Thursday,
September 21, 2006.
"Obtaining
a NASDAQ Capital Market listing is an important step forward in the Company's
development," said Jon Lewis, Chief Executive Officer. "We are excited about
this milestone and believe that a NASDAQ listing will benefit current and future
shareholders by increasing the Company's visibility and access in the investment
community and helping to generate demand for our stock."
About
ZIOPHARM Oncology, Inc.
ZIOPHARM
Oncology, Inc. is a biopharmaceutical company engaged in the development and
commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer
drugs to address unmet medical needs. The Company applies new insights from
molecular and cancer biology to understand the efficacy and safety limitations
of approved and developmental cancer therapies and identifies proprietary and
related molecules for better patient treatment. For more information, visit
www.ziopharm.com.
Forward-Looking
Safe Harbor Statement:
This
press release contains forward-looking statements for ZIOPHARM Oncology, Inc.
that involve risks and uncertainties that could cause the Company's actual
results to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are based on
current expectations, forecasts and assumptions that are subject to risks and
uncertainties, which could cause actual outcomes and results to differ
materially from these statements. Among other things, there can be no assurance
that any of the Company's development efforts relating to its product candidates
will be successful, or such product candidates will be successfully
commercialized. Other risks that affect forward-looking information contained
in
this press release include the possibility of being unable to obtain regulatory
approval of the Company's product candidates, the risk that the results of
clinical trials may not support the Company's claims, and risks related to
the
Company's ability to protect its intellectual property and its reliance on
third
parties to develop its product candidates. The Company assumes no obligation
to
update these forward-looking statements, except as required by law.